Impact of Far-Infrared-Radiation on the Proportion of Interventions in Arteriovenous Fistulas in Patients on Hemodialysis

INTRODUCTION: In patients on hemodialysis, the risk of arteriovenous fistula (AVF) failure is unacceptably high. Up to 67% of AVFs need an intervention within one year after placement. There are no effective treatments to prolong AVF longevity. Far Infrared radiation (FIR) treatment has been suggested to enhance AVF survival. The present trial investigated the effect of FIR on the proportion of interventions in the AVF. METHODS: In a multicenter, randomized, controlled trial, patients were allocated to receive FIR treatment or no FIR. Eligible patients were patients on chronic hemodialysis with a well-functioning AVF. The FIR group received FIR above the skin of their AVF for 40 minutes at every hemodialysis (HD)session for one year. The primary outcome was the difference in the proportion of patients with at least one intervention (thrombectomy or percutaneous transluminal angioplasty) after 12 months. The Chi-square test analyzed the difference. Secondary outcomes included differences in the number of thrombosed AVFs, intervention rate, access flow at various time points, and time to first intervention between groups. RESULTS: A total of 115 patients were randomized to the FIR group (n=58) or the control group (n=57). Baseline characteristics were similar in both groups. There was no significant difference in the proportion of patients with interventions between the FIR and control groups (19% vs. 28%, p=0.25) or in the proportion with thrombosed AVFs (5% vs. 3%, p = 0.26). Time to first intervention was 164 (IQR 86;272) days in the FIR group and 127 (IQR 44;164) days in the control group(p=0.26). No differences in the change of access flow occurred (p=0.86). CONCLUSION: During 12 months of treatment, FIR did not affect the overall patency of the AVF. No difference was found in the number of patients with interventions or in any of the secondary endpoints. (Clinicaltrials.gov: NCT04011072).

Authors

Institutions

Publication Details

Journal
Clinical Journal of the American Society of Nephrology
Published
2026-06-12
DOI
https://doi.org/10.2215/cjn.0000001079
Primary Topic
Central Venous Catheters and Hemodialysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Far-Infrared-Radiation on the Proportion of Interventions in Arteriovenous Fistulas in Patients on Hemodialysis

Mahshid Pourarsalan, Marianne Rix, Emilie Klara Hansen, Ylian S. Liem et al.
Clinical Journal of the American Society of Nephrology
Central Venous Catheters and Hemodialysis
article

Impact of Far-Infrared-Radiation on the Proportion of Interventions in Arteriovenous Fistulas in Patients on Hemodialysis

Mahshid Pourarsalan, Marianne Rix, Emilie Klara Hansen, Ylian S. Liem, Henrik Post Hansen, Boye L. Jensen, Ditte Hansen, Kristine Lindhard, Kristine Hommel, Brian Pedersen, Kirstine Gliese, James Heaf
article en

Abstract

INTRODUCTION: In patients on hemodialysis, the risk of arteriovenous fistula (AVF) failure is unacceptably high. Up to 67% of AVFs need an intervention within one year after placement. There are no effective treatments to prolong AVF longevity. Far Infrared radiation (FIR) treatment has been suggested to enhance AVF survival. The present trial investigated the effect of FIR on the proportion of interventions in the AVF. METHODS: In a multicenter, randomized, controlled trial, patients were allocated to receive FIR treatment or no FIR. Eligible patients were patients on chronic hemodialysis with a well-functioning AVF. The FIR group received FIR above the skin of their AVF for 40 minutes at every hemodialysis (HD)session for one year. The primary outcome was the difference in the proportion of patients with at least one intervention (thrombectomy or percutaneous transluminal angioplasty) after 12 months. The Chi-square test analyzed the difference. Secondary outcomes included differences in the number of thrombosed AVFs, intervention rate, access flow at various time points, and time to first intervention between groups. RESULTS: A total of 115 patients were randomized to the FIR group (n=58) or the control group (n=57). Baseline characteristics were similar in both groups. There was no significant difference in the proportion of patients with interventions between the FIR and control groups (19% vs. 28%, p=0.25) or in the proportion with thrombosed AVFs (5% vs. 3%, p = 0.26). Time to first intervention was 164 (IQR 86;272) days in the FIR group and 127 (IQR 44;164) days in the control group(p=0.26). No differences in the change of access flow occurred (p=0.86). CONCLUSION: During 12 months of treatment, FIR did not affect the overall patency of the AVF. No difference was found in the number of patients with interventions or in any of the secondary endpoints. (Clinicaltrials.gov: NCT04011072).

Clinical Journal of the American Society of Nephrology
University of Copenhagen (DK), University of Southern Denmark (DK), Herlev Hospital (DK), Copenhagen University Hospital (DK), Rigshospitalet (DK), Zealand University Hospital (DK), Holbæk Sygehus (DK), Regional Hospital Central Jutland (DK)
Good health and well-being
Openalex Percentile: Top 4%
Central Venous Catheters and Hemodialysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.